Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

• Published in: Neuropsychopharmacology (New York, N.Y.) Vol. 28; no. 9; pp. 1685 - 1693
• Main Authors: Chalon, Stephan A, Granier, Luc-André, Vandenhende, François R, Bieck, Peter R, Bymaster, Frank P, Joliat, Melissa J, Hirth, Christine, Potter, William Z
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2003; Nature Publishing; Nature Publishing Group
• Subjects: Adult; Antidepressive Agents - pharmacology; Behavioral Sciences; Biological and medical sciences; Biological Psychology; Blood Pressure - drug effects; Cross-Over Studies; Desipramine - administration & dosage; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Heart Rate - drug effects; Humans; Male; Mandelic Acids - urine; Medical sciences; Medicine; Medicine & Public Health; Methoxyhydroxyphenylglycol - urine; Neuropharmacology; Neurosciences; Norepinephrine - urine; Normetanephrine - urine; original-article; Pharmacology. Drug treatments; Pharmacotherapy; Psychiatry; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Serotonin - blood; Sympathomimetics - administration & dosage; Thiophenes - pharmacology; Time Factors; Tyramine - administration & dosage; Tyramine - adverse effects; Tyramine - pharmacokinetics; norepinephrine; neurotransmitter uptake inhibitors; antidepressive agents; serotonin; Human; Urine; Biological fluid; Healthy subject; Serotonin; Psychotropic; Volunteer; Oral administration; Bioavailability; Duloxetine; Reuptake inhibitor; Blood plasma; Double blind study; Neurotransmitter; Antidepressant agent; Norepinephrine; Mechanism of action; Pharmacokinetics

Evidence suggests that compounds that increase the synaptic availability of more than one neurotransmitter have greater efficacy in the treatment of depression than single-acting drugs. Preclinical studies indicate that duloxetine acts to inhibit serotonin (5-HT) and norepinephrine (NE) transporters...